StoneX Forecasts Strong Price Appreciation for Agilon Health (NYSE:AGL) Stock

Agilon Health (NYSE:AGL) had its price objective raised by StoneX from $140.00 to $145.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. StoneX‘s price target indicates a potential upside of 26.35% from the stock’s previous close.

AGL has been the topic of a number of other reports. Royal Bank Of Canada set a $125.00 price target on Agilon Health in a report on Tuesday, September 15th. Wells Fargo & Company reiterated an “overweight” rating and issued a $146.00 price objective (up from $141.00) on shares of Agilon Health in a research note on Tuesday, August 11th. Robert W. Baird set a $116.00 price objective on shares of Agilon Health in a research note on Thursday, August 6th. Barclays set a $111.00 target price on shares of Agilon Health and gave the company an “equal weight” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research note on Monday, August 24th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $105.54.

Agilon Health Stock Up 1.1%

Shares of NYSE:AGL opened at $114.77 on Wednesday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -20.68 and a beta of 3.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.13 and a quick ratio of 1.13. The business’s 50-day moving average is $89.65 and its 200-day moving average is $68.07. Agilon Health has a 1 year low of $7.48 and a 1 year high of $133.04.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, November 4th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of ($1.23) by $3.20. Agilon Health had a negative return on equity of 51.97% and a negative net margin of 1.45%. The business had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Equities research analysts predict that Agilon Health will post -2.90 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGL. Tidal Investments LLC acquired a new stake in Agilon Health in the second quarter valued at approximately $1,405,000. Rubicon Founders LLC bought a new stake in shares of Agilon Health in the 2nd quarter worth $11,290,448. State Street Corp purchased a new stake in Agilon Health in the 2nd quarter valued at about $30,024,000. Ellsworth Advisors LLC bought a new stake in Agilon Health during the third quarter worth $809,000. Finally, Great Lakes Advisors LLC bought a new stake in shares of Agilon Health during the 2nd quarter worth $702,000.

About Agilon Health

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.